Biognosys is proud to announce the presentation of two posters at the 35th Anniversary
Annual Meeting of the Society for Immunotherapy of Cancer (SITC):
Discovery of Ganglioside GM2 Activator as a Novel Proteomic Biomarker Associated with Response to Treatment in First-line Melanoma Subjects Treated with PD-1 Immunotherapy
K. Beeler1, J. Vowinckel1, M. Soste1, D. Mallardo2, M. Capone2, M. Gabriele2, A. Sorrentino2, V. Vanella2, K. Sklodowski2, D. Heinzmann2, P. Ascierto2
1) Biognosys AG, Schlieren (Zurich), Switzerland 2) Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy
Integrating Deep Proteomic Profiling with Survival Analysis to Identify Novel Biomarkers of Response to PD-1 Blockade in NSCLC Patients
V. Dozio1, S. Lopez-Lastra3, A. Lanzós1, K. Sklodowski1, K. Beeler1, E. Romano2, 3
1) Biognosys AG, Schlieren (Zurich), Switzerland 2) Medical Oncology Department, Institut Curie, Paris, France 3) Center for Cancer Immunotherapy, Institut Curie, Paris, France
The ESMO Virtual Exhibition takes place from Tuesday 10 November to Sunday 15 November 2020. Check out our virtual booth and chat live with our team via the virtual platform.
More information about our offerings for Oncology Research is available
More information about our offerings for Clinical Studies is available
More information about our offerings for Pre-clinical Evaluation is available
More information about our offerings for Discovery Biology is available
Book a meeting with our team to get your personal presentation of our posters!
Request a consultation with our proteomics experts to explore how our proteomics platform can accelerate your research!
Biognosys AG
Wagistrasse 21
8952 Schlieren
Switzerland
Phone: +41 44 738 20 40
US Offices
Biognosys Inc
70 Bridge St, Suite 104
Newton, MA 02458
United States
